Alexion Pharmaceuticals, Inc. (ALXN) SVP Sells $76,805.30 in Stock

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) SVP Heidi L. Wagner sold 655 shares of the stock in a transaction on Monday, February 5th. The stock was sold at an average price of $117.26, for a total value of $76,805.30. Following the completion of the sale, the senior vice president now directly owns 32,635 shares in the company, valued at $3,826,780.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded down $3.04 during mid-day trading on Thursday, reaching $114.11. The company had a trading volume of 1,872,629 shares, compared to its average volume of 1,969,899. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $96.18 and a fifty-two week high of $149.34. The company has a market capitalization of $25,400.00, a PE ratio of 50.73, a P/E/G ratio of 0.96 and a beta of 1.16. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.96 and a quick ratio of 2.51.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.27 by $0.21. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The business had revenue of $909.70 million during the quarter, compared to analysts’ expectations of $880.38 million. During the same quarter last year, the business posted $1.26 earnings per share. The company’s quarterly revenue was up 9.5% on a year-over-year basis. sell-side analysts expect that Alexion Pharmaceuticals, Inc. will post 4.82 EPS for the current year.

A number of hedge funds have recently made changes to their positions in ALXN. Jennison Associates LLC boosted its stake in Alexion Pharmaceuticals by 720.0% during the third quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock valued at $748,116,000 after buying an additional 4,682,336 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in Alexion Pharmaceuticals by 4,509.0% during the third quarter. Assenagon Asset Management S.A. now owns 884,150 shares of the biopharmaceutical company’s stock valued at $124,037,000 after buying an additional 864,967 shares in the last quarter. Alkeon Capital Management LLC bought a new position in Alexion Pharmaceuticals during the third quarter valued at about $70,145,000. Wells Fargo & Company MN boosted its position in shares of Alexion Pharmaceuticals by 32.7% in the 3rd quarter. Wells Fargo & Company MN now owns 1,558,531 shares of the biopharmaceutical company’s stock valued at $218,647,000 after purchasing an additional 383,713 shares during the period. Finally, Pictet Asset Management Ltd. boosted its position in shares of Alexion Pharmaceuticals by 46.7% in the 3rd quarter. Pictet Asset Management Ltd. now owns 1,126,275 shares of the biopharmaceutical company’s stock valued at $158,005,000 after purchasing an additional 358,695 shares during the period. 94.04% of the stock is owned by institutional investors and hedge funds.

Several brokerages have weighed in on ALXN. Evercore ISI raised Alexion Pharmaceuticals from an “in-line” rating to an “outperform” rating in a research report on Monday. Leerink Swann reaffirmed a “buy” rating and issued a $169.00 target price on shares of Alexion Pharmaceuticals in a research report on Wednesday, December 6th. Raymond James Financial reaffirmed an “outperform” rating and issued a $130.00 target price (down from $178.00) on shares of Alexion Pharmaceuticals in a research report on Thursday, January 4th. They noted that the move was a valuation call. Royal Bank of Canada raised their price target on Alexion Pharmaceuticals to $166.00 in a report on Tuesday, October 24th. Finally, TheStreet lowered Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Friday, November 10th. One analyst has rated the stock with a sell rating, two have issued a hold rating and twenty have given a buy rating to the company. Alexion Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $153.10.

COPYRIGHT VIOLATION NOTICE: This piece was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.com-unik.info/2018/02/08/alexion-pharmaceuticals-inc-alxn-svp-sells-76805-30-in-stock.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Insider Buying and Selling by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit